1. Home
  2. NCA vs CRDF Comparison

NCA vs CRDF Comparison

Compare NCA & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NCA
  • CRDF
  • Stock Information
  • Founded
  • NCA 1987
  • CRDF 1999
  • Country
  • NCA United States
  • CRDF United States
  • Employees
  • NCA N/A
  • CRDF N/A
  • Industry
  • NCA Investment Managers
  • CRDF Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NCA Finance
  • CRDF Health Care
  • Exchange
  • NCA Nasdaq
  • CRDF Nasdaq
  • Market Cap
  • NCA N/A
  • CRDF 196.2M
  • IPO Year
  • NCA N/A
  • CRDF N/A
  • Fundamental
  • Price
  • NCA $8.64
  • CRDF $2.63
  • Analyst Decision
  • NCA
  • CRDF Strong Buy
  • Analyst Count
  • NCA 0
  • CRDF 4
  • Target Price
  • NCA N/A
  • CRDF $12.00
  • AVG Volume (30 Days)
  • NCA 59.6K
  • CRDF 1.1M
  • Earning Date
  • NCA 01-01-0001
  • CRDF 05-20-2025
  • Dividend Yield
  • NCA 3.92%
  • CRDF N/A
  • EPS Growth
  • NCA N/A
  • CRDF N/A
  • EPS
  • NCA N/A
  • CRDF N/A
  • Revenue
  • NCA N/A
  • CRDF $683,000.00
  • Revenue This Year
  • NCA N/A
  • CRDF N/A
  • Revenue Next Year
  • NCA N/A
  • CRDF N/A
  • P/E Ratio
  • NCA N/A
  • CRDF N/A
  • Revenue Growth
  • NCA N/A
  • CRDF 39.96
  • 52 Week Low
  • NCA $7.77
  • CRDF $2.01
  • 52 Week High
  • NCA $9.12
  • CRDF $5.64
  • Technical
  • Relative Strength Index (RSI)
  • NCA 62.72
  • CRDF 41.22
  • Support Level
  • NCA $8.42
  • CRDF $2.42
  • Resistance Level
  • NCA $8.58
  • CRDF $2.87
  • Average True Range (ATR)
  • NCA 0.09
  • CRDF 0.18
  • MACD
  • NCA 0.03
  • CRDF 0.01
  • Stochastic Oscillator
  • NCA 100.00
  • CRDF 24.42

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Share on Social Networks: